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A B S T R A C T 
Fused deposition modelling (FDM) 3D printing has shown the most immediate potential for 
on-demand dose personalisation to suit particular patient’s needs. However, FDM 3D printing 
often involves employing a relatively large molecular weight thermoplastic polymer and results 
in extended release pattern. It is therefore essential to fast-track drug release from the 3D 
printed objects. This work employed an innovative design approach of tablets with unique 
built-in gaps (Gaplets) with the aim of accelerating drug release. The novel tablet design is 
composed of 9 repeating units (blocks) connected with 3 bridges to allow the generation of 8 
gaps. The impact of size of the block, the number of bridges and the spacing between different 
blocks were investigated. Increasing the inter-block spaces reduced mechanical resistance of 
the unit, however, tablets continued to meet pharmacopeial standards for tablet’s friability. 
Upon introduction into gastric medium, 1 mm spaces tablet broke into mini-structures within 
4 min and met the USP criteria of immediate release products (86.7% drug release at 30 min). 
Real-time ultraviolet (UV) imaging indicated that the cellulosic matrix has expanded due to 
swelling of HPC upon introduction to dissolution medium. This was followed by a steady 
erosion of the polymeric matrix at a rate of 8 µm/min. The design approach was more efficient 
than formulation approach of adding disintegrants to accelerate tablet disintegration and drug 
release. This work provides a unique example where computer-aided design was instrumental 
at modifying the performance of solid dosage forms. Such an example may serve as a 
foundation for a new generation of dosage forms with complicated geometric structures to 
achieve functionality that are usually reached by formulation approach. 
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1. Introduction  
With the increased focus on personalised patient treatment, the search for methods that offer 
flexibility in the customization of  dosage forms is in high demand. Three-dimensional (3D) 
printing technologies provide a tool for tailoring dosage forms and are strongly paving their 
way into the future of oral drug delivery. Indeed, 3D printing technologies have the ability to 
fabricate designs and complex geometries that were not possible with traditionally 
manufactured dosage forms. This highly attractive technology has the capability of creating 
hollow or partially filled designs as well as the creation of constructs with complex drug release 
profiles (Alhnan et al., 2016; Goole and Amighi, 2016; Lam et al., 2002). This ability has been 
exploited to fabricate tablets with dual, pulsatory and/or immediate-extended release profiles 
(Rowe et al., 2000).  
Despite the many attractive properties of the 3D printing technologies, fused deposition 
modelling (FDM) in particular, seems to hold more potential due to its capability in fabricating 
mechanically stable tablets at low cost without post-processing processes (Goyanes et al., 2015; 
Skowyra et al., 2015) or specialised powder facilities (Alhnan et al., 2016). Nonetheless, this 
technology is hindered by the elevated temperatures required for its operation as well as the 
restricted number of eroding polymers with thermoplastic properties suitable for FDM 3D 
printing (Goyanes et al., 2015; Skowyra et al., 2015). To address these limitations, research 
efforts to apply FDM 3D printing to different pharmaceutical grade polymers such as 
polyvinylpyrrolidone (Okwuosa et al., 2016), methacrylate (Sadia et al., 2016) and cellulose 
based polymers (Goyanes et al., 2017; Skowyra et al., 2015; Zhang et al., 2017) have been 
recently reported. 
As the use of a thermoplastic polymer with a relatively high glass transition temperature is a 
pre-requisite for a successful and complete FDM 3D printing process, the resultant structures 
have often incorporated relatively high molecular weight polymers to yield a polymeric matrix 
resulting in extended drug release patterns (Goyanes et al., 2014; Goyanes et al., 2015; 
Skowyra et al., 2015). Due to the importance of the immediate release market, holding 70% of 
total oral tablet market share (GBIResearch, 2012; Marketsandmarkets, 2013) and the high 
safety profile of cellulosic polymers e.g. hydroxypropyl cellulose (HPC) in the pharmaceutical 
and food industry, it is therefore of major interest to craft an immediate release tablet out of 
this widely used pharmaceutical grade polymer.  
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Several researchers have exploited a design approach to modify drug release from a 3D printed 
structure. Sun and Soh (2015) modified matrix shape to achieve increasing, decreasing, 
constant or pulsed release of an entrapped dye. The geometric shape of the 3D printed tablet 
also appeared to influence to some degree the pattern of in vitro drug release (Goyanes et al., 
2015). Moreover, employing different infill percentage in the 3D printed structure  is another 
approach to modify drug release. However, this approach often results in a low density floating 
structures and does not accelerate drug release to an extent that meets the compendial 
expectations of immediate release products (Goyanes et al., 2014; Kyobula et al., 2017; Tagami 
et al., 2017). 
In this study, a novel design approach (Gaplet) for accelerating drug release from FDM 3D 
printed cellulosic tablets is presented. The approach is based on utilising FDM’s capability to 
construct relatively complex geometry designs that deliver a collapsible tablet structure. The 
tablets were made using the novel concept of interconnected blocks to generate intra-tablet 
gaps with the aim of rapid fragmentation within minutes on exposure to a dissolution medium. 
According to the authors’ knowledge, this is the first work successfully detailing such a design 
concept in 3D-printed dosage forms.  
2. Materials and methods 
 
2.1 Materials 
Theophylline was purchased from Arcos (United Kingdom (UK)). Hydroxypropyl cellulose 
(SSL grade) was provided by Nisso Chemical Europe GmbH (Dusseldorf, Germany). Triacetin 
was supplied by Sigma–Aldrich (UK). Sodium starch glycolate (Primojel® and Explotab®) 
were donated by DFE Pharma (Germany) and JRS pharma LP (United States of America 
(USA)) respectively. Croscarmellose sodium grades (Ac-Di-Sol® and Primellose®) were 
provided by FMC Biopolymer (USA) and DFE Pharma (Germany) respectively. Crospovidone 
(Polyplasdone™ XL-10) was donated by Ashland (USA).  
2.2 Preparation and optimisation of filaments via hot-melt extrusion (HME) 
A twin-screw hot melt extruder (Thermo Scientific™ HAAKE™ MiniCTW, Karlsruhe, 
Germany) was employed to produce a filament as a feed for the 3D printer. The compositions 
of the mixtures of drug, polymer and plasticizer were adapted and modified from a previous 
trial (Skowyra et al., 2015). Briefly, 12 g of theophylline, HPC-SSL and triacetin blend at a 
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weight ratio of (50:45:5) was accurately weighed and added gradually to the counter flow twin-
screw extruder. The molten mass was homogenised for a minimum of 5 min at a rotation speed 
of 80 rpm to allow consistent distribution of the drug and the polymer. The specific temperature 
of initial feeding extrusion and extrusion was 120 °C. Extrusion was carried out through a 1.7 
mm die nozzle with using a torque control of 0.8 Nm. Filaments were stored in sealed plastic 
bags at room temperature and were used as a feed for FDM 3D printing within 3 weeks of 
manufacture. To assess the effect of disintegrants on the formulations, Ac-Di-Sol®, Explotab®, 
Primojel®, Polyplasdone ™ XL-10 were added individually to the powder mixture at a weight 
ratio of (45:45:5:5) for theophylline, HPC-SSL, triacetin and the disintegrant. 
2.3 Design and printing of tablets 
A Makerbot Replicator® 2X Experimental 3D printer (Makerbot Industries, LLC, New York, 
USA) has been utilized to fabricate the 3D printed tablets from the HME based filament. 
Prototypes of product designs were developed with computer-aided design (CAD) software, 
Autodesk® 3ds Max Design 2016 software version 18.0 (Autodesk, Inc., USA). The obtained 
files were converted into a printer-readable format and imported to the printer’s software 
(Makerbot Desktop version 2.4.0.17 Makerbot Industries, LLC, New York, USA) in an STL 
format. Tablets were printed using modified settings of the software for PLA filament as 
follows: type of printer: Replicator 2X; type of filament: PLA; resolution: standard; the speed 
material flow from extruder: 70 mm/s, speed of extruder travelling: 150 mm/s while traveling; 
infill: 100%; printer’s nozzle size: 0.4 mm, height of the layer: 300 µm. To obviate the need of 
a post-print finishing step, tablets were printed without the use of supports or rafts. 
The novel design (Gaplet) is a jointed system, developed by crafting tablets in a capsule-like 
structure divided into nine blocks with determined 8 spaces in between (Figs. 1a, b). Initially, 
3 sets of tablets with block widths: 0.5, 1 or 1.5 mm were designed. Each set were printed with 
increasing inter-block spaces: 0, 0.2, 0.4, 0.6, 0.8, 1.0 or 1.2 mm (Fig. 1c). The blocks within 
each tablet were constructed with three bridges (600 µm) connecting the blocks. The resolution 
was set at a layer thickness of 0.3 mm. The theoretical dimensions, volume, surface area and 
volume of these designs as reported by Autodesk® 3ds Max Design 2016 software are available 
in Table 1. 
2.4 Thermal analysis 
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Samples (raw materials, extruded filaments and printed tablets) were characterised using 
differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). 
For DSC analysis, a differential scanning calorimeter DSC Q2000 (TA Instruments, Elstree, 
Hertfordshire, UK) with a heating rate of 10 °C/min was used. Samples were heated to 100 °C 
for 5 min to exclude the effect of humidity then cooled to −20 °C. This was followed by a heat 
scan from −20 to 300 °C. Analysis was carried out under a purge of nitrogen (50 mL/min). The 
data was analysed using TA 2000 analysis software. Standard 40-µL TA aluminium pans and 
pin-holed lids were used with an approximate sample mass of 5 mg. All measurements were 
carried out in triplicates. 
For TGA analysis, raw materials, extruded filaments and 3D printed tablets were measured 
using a TGA Q500 (TA Instruments, Hertfordshire, UK). Samples (5 mg) were placed in 40 
µL aluminium pans and were scanned from 25 to 500 °C at a heating rate of 10 °C/min. The 
thermal decomposition (or degradation) profile was analysed using STARE software version 
9.00. The experiments were carried out under a nitrogen gas flow of 50 mL/min. All 
measurements were carried out in triplicates. 
2.5 X-ray powder diffraction (XRD) 
A powder X-ray diffractometer, D2 Phaser with Lynxeye (Bruker, Germany) was used to 
assess the physical form of theophylline in the drug loaded tablets. Samples were scanned from 
2Theta = 5° to 50° using 0.01° step width and a 1 sec time count. The divergence slit was 1 mm 
and the scatter slit 0.6 mm. The wavelength of the X-ray was 0.154 nm using Cu source and a 
voltage of 30 kV. Filament emission was 10 mA using a scan type coupled with a two-
theta/theta scintillation counter over 30 min. 
2.6 Scanning Electron Microscopy (SEM) 
The surface morphology of the printed tablets was assessed using a Quanta-200 SEM 
microscope at 20 kV. All samples were placed on a metallic stub and gold plated using a JFC-
1200 Fine Coater (Jeol, Tokyo, Japan). Photographs of the tablets were captured with a Canon 
EOS-1D Mark IV (Canon Ltd, Japan). Digital photographs of the 3D printed tablets were 
acquired, using a Canon™ EOS 100D digital camera with EF-S 18-55 mm lens. 
2.7 X-ray micro-computed tomography (XμCT) 
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A Skyscan µCT 1272 (Skyscan, Kontich, Belgium) was used for the morphological analysis of 
the 3D printed Gaplets (Whole) (parameters: source voltage = 52 kV, source current = 85 μA, 
and image pixel size = 4.3 μm, 360o of rotation). NRecon software (version 1.6.9.8; Bruker 
µCT) was used for the reconstruction of the images, whilst DataViewer (Version 1.4.4; Bruker 
µCT) and CTVox (version 2.6.0; Bruker µCT) software were used to process the images 
datasets and to produce the virtual slices. 
2.8 Mechanical property of the tablet.  
a. Crushing strength: To evaluate the impact of the built-in gap design on the mechanical 
resistance of 3D printed tablets; a crushing strength tester (200 Tablet Hardness Tester, Agilent 
Technologies) was employed. The measured forces were intended to characterize a tablet’s 
resistance to crushing. The tablet’s long axis was oriented in the same direction of force 
application in the crushing strength tester. Measurements were carried out in triplicate. 
b. Friability test: In order to assess the suitability of the tablet for daily handling and packaging, 
a friability test has been conducted. Tablets (20 units) were accurately weighed, placed in the 
apparatus drum (Agilent Dual-drum Friability Tester 250, Agilent Technologies) and rotated 
100 times at rotation speed of 25 round/min. 
 c. Tensile strength test: An Instron® 5569 tensile tester (Illinois Tool Works Inc., US) was 
employed to study the tensile strength of the tablets. Scanning was performed under extension 
mode to calculate the tensile strength. Tensile strength was measured at room temperature (21 
°C) and relative humidity of 50%. Samples were measured using circular geometry with data 
collection interval of 0.05 sec. Sample diameter (average 1.8 mm)  with a gauge length of 10 
mm was used and the final length after extension was 20 mm. The extension rate was set as 1 
mm/min. Before each scan, clamp’s load was tared after positioning the gauge using the auto-
home function. Tablets which broke at the holding point were excluded from the study to rule 
out the artefact of power concentration at clamping point. Each measurement was recorded as 
the mean of four replicates. 
2.9 Weight uniformity 
Ten tablets were randomly selected and weighed using a Discovery DV215CD digital balance 
(Ohaus Corporation, USA). The average mass, standard deviation and percentage deviation 
from average mass were determined for each design.  
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2.10 In vitro drug release testing 
The impact of tablet design on the release pattern of the 3D printed tablets was assessed using 
a United States Pharmacopeia (USP II) dissolution test apparatus (Erweka GmbH, Germany). 
The dissolution test was adapted from the USP monograph for immediate release theophylline 
tablets (USP, 2007). The dissolution study was conducted in 900 mL of 0.1 M hydrochloric 
acid (pH 1.2) at 37 ± 0.5 °C and with paddle speed of 50 rpm. The amount of released 
theophylline was determined at 5 min intervals by UV/VIS spectrophotometer (PG Instruments 
Limited, UK) at the wavelength of 272 nm and path length of 1 mm. Data was analysed using 
IDISis software (Automated Lab, UK, 2012). The concentration of theophylline was calculated 
using a calibration curve of standard drug solutions in the acidic medium (concentration range: 
10-250 mg/L, Linear equation: Ab=0.00535 C+0.00134, where Ab is UV absorbance and C is 
theophylline concentration in mg/L, and coefficient of determination R2 = 0.9996). Each 
sample was tested in trilicate and in vitro release patterns of theophylline were plotted versus 
time using the average percentage value with error bars representing the standard deviation. In 
order to assess the disintegration behaviour of the 3D printed tablet during the dissolution test, 
the dissolution was video-recorded using a Sony HXR-NX3 camera (Sony Electronics Inc., 
Japan) with the macro option on. Wide-angle green laser probes were used to illuminate the 
tablets during dissolution in a dark room.  
To assess the swelling behaviour of cellulosic matrix in the dissolution medium as well as drug 
diffusion pattern, real-time UV imaging for the polymeric matrix was assessed using an Actipix 
SDI300 dissolution imaging system (Paraytec Ltd., York, UK) with Actipix flow-through type 
dissolution cartridge. The sample was exposed therefore to the dissolution media through one 
surface only (area of 12.57mm2).  The dissolution media was flowing over the top surface using 
a UV filter of 280 nm. The collection of the data was achieved using SDI Online Mode software 
(v 1.8.50805, Paraytec Ltd, York, UK). The obtained data were analysed using SDI Offline 
Mode software (v1.8.50805, Paraytec Ltd, York, UK). The software allowed the conversion of 
the data from UV measurement into drug concertation after the input of drug’s absorptivity. 
2.11 Statistical analysis 
One-way analysis of variance (ANOVA) was employed using SPSS Software (22.0.0.2) to 
analyse the differences in the percentage of drug released at T=30 min. Differences in results 
where p≤ 0.05 were considered significant, and  p of >0.05 was considered not significant. 
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3. Results and discussion 
As illustrated in Fig.1, a range of tablets with built-in gaps were engineered with the design 
aim of breaking rapidly upon contact with aqueous medium. The tablets were composed of 9 
repeated units (blocks) that are connected together with three bridges: two at the bottom and 
top of the tablet and a third at the mid-level of the tablet structure. Initially, 3 sets of tablets 
with block widths (0.5, 1 or 1.5 mm) were designed. Each set was printed with increasing inter-
block spacing: namely 0, 0.2, 0.4, 0.6, 0.8, 1.0 or 1.2 mm.  
A theophylline loaded cellulosic filament processed by HME extrusion was used as a feed for 
FDM 3D printing to fabricate these designs. TGA data indicated minimal weight loss following 
the two thermal processes of HME and FDM 3D printing, and suggested that tablet contents 
remained stable under the processing conditions (Fig. 2A). Thermal analysis data indicated that 
a portion of theophylline remained in a crystalline form based on the presence of a melting 
peak at 258 oC (Fig. 2B). The same DSC thermal scan also showed that the filament has a glass 
transition temperature (Tg) of 46 oC and was compatible with FDM 3D printing process. The 
additional thermal processing of the filament through a FDM 3D printer nozzle did not seem 
to significantly affect the Tg or the drug’s melting point in the tablet (Fig. 2B). XRD patterns 
of the filament and 3D printed tablets confirmed the crystalline nature of theophylline in the 
cellulosic matrix in both filament and 3D printed tablet (Supplementary data, Fig. S1C) with 
the presence of intensity peaks at 2Theta = 7 o, 12 o, 14 o and 24o that are typical of theophylline 
crystals (Rasanen et al., 2001). 
Figs. 3A and 3B show rendered images and photographs of sets of 1 mm blocks (Images of a 
printed set of tablets with 1.5mm width blocks are shown in Supplementary Data, Fig. S1). The 
use of the bridge system design allowed for a structurally stable tablet to result from and during 
the printing process: the lower bridge allows the building of a base for the tablet and facilitated 
tablet recovery upon completion of the 3D printing process. The middle and upper bridges 
helps the formation of coherent and easy-to-handle tablets. SEM images confirmed that the gap 
spaces were parallel to the blocks as envisaged in the design (Fig. 3C). However, when designs 
of a thinner block (0.5 mm) were printed, they yielded distorted and incomplete structures and 
were concluded as unsuitable.  The limited resolution of FDM 3D printing (Armillotta, 2006) 
was the likely reason for the distortion. 
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The internal structure of the 3D printed tablet was assessed using XµCT technique (Fig. 4). 
The technique confirmed the consistent parallel blocks and spaces throughout the tablet layers. 
Each block was composed of 3 lines of 300 µm wide fused extrudates and were connected by 
three bridges at right angles to the central axis of the block. In general, the quality of the printed 
design were lower than what is usually achieved with FDM 3D printing. It is possible that due 
to the complicated nature of the design, the flow of the material is frequently interrupted with 
numerous stop-start orders of the moving heads. The stop-start process may have contributed 
to the fluctuation in the weight of printed tablet (Table 1). In addition, the shallowness of the 
blocks of the structure in CAD designs negates the possibility of using shell layer(s) to cover 
the internal core as commonly used in FDM 3D printing.  
The impact of design on the mechanical properties of the constructed tablets was assessed via 
examining tablet crushing and tensile strength as well as friability. The material of fabrication 
for the 3D printed tablets is the same and in theory should have the same the hardness and 
disintegration time. However, the presence of weak bridges creates weak points that tend to 
break first in a crushing test (whilst the constituent block components remains intact). 
Increasing inter-block spaces led to significant reduction in tablet crushing strength (p<0.05). 
A stark difference was noted for solid tablets (without spaces), which exhibited a crushing 
strength of 227 N in comparison to 17 N for the 1.2 mm spaced blocks (Table 1). It is worth 
noting that crushing of these tablets is fundamentally different to that of tablet produced by 
powder compression, where cracks are initiated in the compressed tablet at defect point(s) and 
propagate across the tablet. In our example, the cracks occur in multiple locations at the 
weakest points (bridges) while the blocks remained intact. 
Tensile strength examination also revealed an inverse relationship between the average 
maximum load at breakage of the tablets and the spacing between the tablets (Table 1). The 
load on the sample is likely to be eccentric due to the inconsistent nature of the structure 
(presence of inter-block spaces). These spaces concentrate the stress on inter-blocks bridges 
and subject them to lateral disturbing load.  Such a trend appeared to be directly related to the 
length of inter-block bridges. Increasing the spaces between the blocks will reduce the 
structural strength hence causes the inter-blocks bridges to fail under the applied stress. 
However, the design impact on crushing and tensile strength of the constructed tablets did not 
affect tablet handling robustness, as indicated from the zero values of friability that was 
obtained for all designs (inter-block spaces 0-1.2 mm) of the HPC-based FDM 3D printed 
tablets (Table 1). 
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The dissolution profiles of in vitro drug release from the 3D printed tablet designs have been 
largely influenced  by the tablet design (Fig.5A for 1 mm block set, see also Supplementary 
Data, Fig. S2 for 1.5 mm set). The rate of in vitro drug release was directly related to the 
distance between the blocks. Tablets with no or 0.2 mm spaces showed a slow drug release 
(<45%) after 30 min. It is worth noting that in tablets of narrow inter-block spacing (0.2 and 
0.4 mm), the blocks tend to swell and a form a gel layer on the surface, this layer facilitates 
blocks adhesion in a random pattern. The blocks can possibly separate after a significant period 
of time (particularly for 0.4mm spacing) and accelerate drug release. This has resulted in 
relatively erratic release patterns (Fig 5A). When larger spacing was employed (≥0.6 mm), the 
separation of the blocks following bridge dissolution was the dominant phenomenon and 
yielded a more predictable release pattern. As a result, drug release was accelerated to >80% 
at T=30 min when the inter-block spacing was increased to 0.6 mm (Fig. 5B). Inter-block 
spaces of 1.0 or 1.2 mm were deemed necessary to meet compendial expectations for 
immediate release products (i.e. >85% release in 30 min). The wider the space between blocks 
in the tablet the less resistance to medium flow through its structure. 
Numerous literature reports indicated that the dissolution of solid dispersion and crystals are 
directly linked to surface area/mass ratio (Armstrong and Haines-Nutt, 1973; Kubo and 
Mizobe, 1997; Nilkumhang et al., 2009; Zhang et al., 2014). However, tablets of inter-block 
spaces of >0.6 mm have only a marginal increase on surface/mass ratio over 0.2 and 0.4 mm 
space block tablets (Table 1). This finding suggests that the marked acceleration of drug release 
when spaces are increased should not only be attributed to a slight increase in surface/mass 
ratio. 
An insight into the mechanism responsible for accelerating drug release from 3D printed tablets 
can be deduced from observation of structural changes during in vitro dissolution. Fig. 6A 
shows the time-to-break of tablets with increasing inter-block spaces during in vitro 
dissolution. Tablets with 0 (solid) and 0.2 mm spaces did not break during dissolution, whilst 
spacing of 0.4 and 0.6 mm allowed a better ingress of the medium into inner surfaces of the 
blocks, causing blocks of the tablet to detach following the dissolution of the bridges. Using 
imaging with wide-angle laser illumination, for an inter-block spacing of 1.2 mm images 
showing tablets breaking into blocks in <6 min was confirmed (Fig. 6B).   
The interaction of the cellulosic matrix of the tablets with simulated gastric dissolution medium 
has been assessed using real-time UV imaging (Fig. 7A). Within the first few minutes, the 
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polymer matrix showed some level of expansion due to swelling of HPC upon introduction of 
dissolution medium. This was followed by a steady erosion of the polymeric matrix at a rate of 
8µm/min (Fig. 7B). For designs of narrower spaces (0.2-0.4 mm), it is possible that the swelling 
of the blocks led to further narrowing of the spaces followed by the fusion of blocks, leading 
to formation of a unit of joined blocks. Such a structure would thus inhibit tablet fragmentation 
as well as drug release in accordance with the in-vitro dissolution data presented earlier.  
Erosion and swelling mechanisms have been previously reported to have major influence on 
drug release from an HPC matrix (Van Nguyen et al., 2016; Vueba et al., 2004). As the 
cellulosic polymer becomes introduced to the aqueous medium, it absorbs water starting from 
the surface leading to progressive polymer hydration, swelling and the formation of a viscous 
gelatinous layer (Korsmeyer and Peppas, 1983). While polymer erosion accelerates release rate 
(Sujja-areevath et al., 1998), swelling tends to retard release with the formation of viscous 
diffusion pathways. In this work, the introduction of gap in the tablet design would appear to 
have prevented the formation of a single large cellulosic matrix and accelerated drug release 
by both facilitating erosion as well as keeping diffusion pathways within swollen individual 
blocks to minimal levels. 
One established approach to accelerate tablet disintegration and dissolution in aqueous 
medium, is through the inclusion of functional additives, disintegrants. In order to compare our 
design approach with the conventional disintegrant addition, several commercially available 
disintegrants were incorporated in the filament composition and printed using solid tablet 
design (no spaces) (Supplementary data, Fig. S3). The addition of the disintegrants was found 
to have no significant effect on in vitro theophylline drug release from the FDM constructed 
tablets. It is worth reporting that even a further increase in disintegrant level  to 10% (w/w) did 
not result in any disintegration effect or acceleration in dissolution rate of the printed tablets. 
This finding of no enhancement was attributed in part to the mechanism of action of these 
disintegrants, which facilitate disintegration via swelling (Alebiowu and Itiola, 2003) and 
wicking (Kissa, 1996) within a compressed powder structure to increase the internal pressure 
and accelerate the dosage form to fall apart. It was also noted that crospovidone may also cause 
disintegration by a shape recovery mechanism upon wetting (Desai et al., 2012). Given the 
intimate mixing that occurs during HME and FDM 3D printing, such disintegration 
mechanisms appear to be greatly disrupted by the thermal processing of disintegrant particles 
with softened/molten polymers.  
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The use of a design approach to enhance the speed of release from an excipient-rich matrix, 
commonly produced via 3D printing technologies, has also been recently reported using a tablet 
design with perforated channels (Sadia et al., 2018) or multi-chamber structure (Kyobula et al., 
2017). Employing design approaches to these systems, means that widely differing release rate 
functionality can be achieved from a single formulation and obviates the need to use different 
formulations to achieve different release rates. This benefit comes with significant cost savings. 
4. Conclusions 
An innovative tablet design approach to include built-in gaps in the 3D printed tablet 
architecture has been demonstrated. The unique tablet design is based on the construction of a 
capsule-shaped tablet with multiple interconnected blocks. Upon introduction to dissolution 
medium, the tablets demonstrated a unique ability to break into mini-structures hence 
accelerating drug release in comparison to solid non-gap-containing 3D printed tablets. A range 
of design attributes were investigated. An inter-block spacing of 1.0 mm was deemed necessary 
for the drug release profile to meet the pharmacopeial criteria of immediate release products. 
The above design was superior to a more conventional formulation approach of including 
disintegrants in 3D tablets to achieve rapid disintegration and dissolution. The innovative 
approach allows one to craft an immediate release cellulosic tablet with substantial drug dose. 
This work also illustrates the potential of employing computer-aided design to construct tablets 
of complex geometries and modify their in vitro performance to meet the mechanical and 
functional expectations of a traditional pharmaceutical product. Whilst the authors have shown 
the potential utility of the design for oral administration, the incorporation of a multi-block 
design can be adopted in the designs of implants or stents where enhancing the release rate of 
an eluting drug from rich polymeric structures is also needed.  
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and increasing inter-block spacing: 0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mm.  C) SEM images of 
inter-channel spaces for these tablets. 
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Fig. 4. Visualisation of XμCT data of the internal structure of the 3D printed tablets (1mm 
block with 1.2 spaces). View from the (A) side, (B) bottom, (C1, C2) X-Y sections across the 
3D printed tablets showing (C1) upper and (C2) middle bridge. 
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Fig. 5. (A) Impact of space distance on in vitro theophylline release into gastric medium from 
3D printed tablets (1 mm block) with increasing spaces (0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mm). 
(B) Drug release (%) after 30 min of dissolution test (USP II paddle 50 rpm, 37 oC, n = 3) 
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Fig. 6. (A) Average time-to-break for tablets during USP II dissolution test in gastric medium 
(USP II paddle 50 rpm, 37 oC, n = 3). Wide angle laser imaging during the first 10 min of USP 
II dissolution test of 3D printed theophylline tablets with (B1) solid tablet design, (B2) 3D 
printed tablet design (1 mm block with 1.2 mm spaces). 
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Fig. 7. UV imaging of in vitro dissolution of theophylline at 272 nm from 3D printed tablet 
vertically positioned in flow-through cell in gastric medium (0.1 M hydrochloric acid, pH 1.2). 
UV images (absorbance) obtained (A1) immediately upon filling of the cell t = 1 min and (A2) 
after the flow of dissolution medium (t = 30 min), (B1) cut-off from profile tracking on Z-axis 
during 30 min of the dissolution process. (B2) the erosion of 3D printed tablet during 
dissolution as measured by changes in the height of iso-absorbance band.  
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Table 1. Spaces of CAD design, dimensions, volume, surface area, surface area/volume ratio of the CAD design, surface 
area/average mass ratio, maximum load and crushing strength of the 3D printed tablets (1 mm block). 
  
Spaces of 
CAD 
design 
(mm) 
 
Dimensions of CAD 
design 
(mm) 
Volume  
of CAD 
design 
(mm3) 
Surface 
area of 
CAD 
design 
(mm2) 
Design 
surface 
area/volu
me ratio of 
CAD design 
(mm -1) 
Tablet mass  Surface 
area/ mass 
ratio  
(mm 2/mg)  
 
Maximum 
load 
(N) ±SD 
Crushing 
strength 
(N) ±SD 
L W H Average 
mass 
(mg) ±SD 
SD% 
0.0 9.9 6.6 7.1 326.7 824.4 2.52 321.9±24.3  7.51 2.55 252.9±27.5 227.5±43.5 
0.2 11.5 6.6 7.1 329.0 840.0 2.65 320.56±26.2 8.18 2.62 159.9±34.5 135±48.2 
0.4 13.2 6.6 7.1 331.8 852.3 2.57 316.77±21.5 6.80 2.69 151.2±44.7 77.5±22.3 
0.6 14.7 6.6 7.1 334.4 864.3 2.58 326.86±1 3.68 2.64 109.6±7.7 53.6±12 
0.8 16.5 6.6 7.1 337.5 879.4 2.61 325.10±12.7  3.90 2.71 63.9±12.1 37.9±8.3 
1.0 18.0 6.6 7.1 339.9 893.5 2.63 337.29±16.2  4.80 2.65 25.8±12.6 25.2±2 
1.2 19.5 6.6 7.1 342.3 907.4 2.65 341.89±19.8  5.80 2.65 18.6±11.3 16.7±2.6 
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Fig. S1. A) Rendered images and B) photographic images of tablet designs with 1.5 mm block and increasing inter-block spacing: 0, 0.2, 0.4, 
0.6, 0.8, 1.0 and 1.2 mm.
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Figure S2. (A) Impact of space distance on in vitro theophylline release to gastric medium from 3D printed tablets (1.5 mm block) with increasing 
spaces (0, 0.2, 0.4, 0.6, 0.8, 1.0 and 1.2 mm). 
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Figure S3. Rendered image (A1) photographic image (A2) of solid tablet (control). (B) SEM images of the two joint blocks. (C) Impact of 
integrating disintegrant on drug release from solid tablet (control). 
 
 
 
